A. Chakravarty

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A. Chakravarty, Arijit Chakravarty
Publication record
113 papers · 1,568 citations · H-index 19

PAPERS

The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis
20234 citationsauthor #10
Antibody escape, the risk of serotype formation, and rapid immune waning: Modeling the implications of SARS-CoV-2 immune evasion
20231 citationsauthor #4
Machine learning for the identification of respiratory viral attachment machinery from sequences data
20230 citationsauthor #4
The gray swan: model-based assessment of the risk of sudden failure of hybrid immunity to SARS-CoV-2
20231 citationsauthor #6
On a model-based approach to improve intranasal spray targeting for respiratory viral infections
202312 citationsauthor #9
Looking under the lamp-post: quantifying the performance of contact tracing in the United States during the SARS-CoV-2 pandemic
20231 citationsauthor #6
Machine Learning for the Identification of Viral Attachment Machinery from Respiratory Virus Sequences
20220 citationsauthor #3
No magic bullet: Limiting in-school transmission in the face of variable SARS-CoV-2 viral loads
20226 citationsauthor #14
Vaccines Alone Cannot Slow the Evolution of SARS-CoV-2
202219 citationsauthor #8
The role of schools in driving SARS-CoV-2 transmission: Not just an open-and-shut case
202217 citationsauthor #3
Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy
20226 citationsauthor #10
Using mixed-effects modeling to estimate decay kinetics of response to SARS-CoV-2 infection
20219 citationsauthor #6
Using translational in vitro-in vivo modeling to improve drug repurposing outcomes for inhaled COVID-19 therapeutics
20211 citationsauthor #3
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
202168 citationsauthor #11
Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure
202119 citationsauthor #8
Detecting in-school transmission of SARS-CoV-2 from case ratios and documented clusters
20216 citationsauthor #7
Individually optimal choices can be collectively disastrous in COVID-19 disease control
202113 citationsauthor #9
Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2
202110 citationsauthor #8
The specter of Manaus: the risks of a rapid return to pre-pandemic conditions after COVID-19 vaccine rollout
20213 citationsauthor #7
Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis
20217 citationsauthor #7
Controlling long-term SARS-CoV-2 infections is important for slowing viral evolution
20213 citationsauthor #6
Beyond the new normal: assessing the feasibility of vaccine-based elimination of SARS-CoV-2
20215 citationsauthor #7
In the long shadow of our best intentions: Model-based assessment of the consequences of school reopening during the COVID-19 pandemic
20209 citationsauthor #6
Abstract 11: An alternative time-to-event metric that is consistent with tumor response speed and depth, unlike RECIST time to progression
20200 citationsauthor #5
COVID-19 isolation and containment strategies for ships: Lessons from the USS Theodore Roosevelt outbreak
20200 citationsauthor #6
Scale-free structure of cancer networks and their vulnerability to hub-directed combination therapy
20202 citationsauthor #6
This time is different: model-based evaluation of the implications of SARS-CoV-2 infection kinetics for disease control
20208 citationsauthor #6
Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein
202023 citationsauthor #11
Identifying the optimal parameters for sprayed and inhaled drug particulates for intranasal targeting of SARS-CoV-2 infection sites.
20202 citationsauthor #3
Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth.
201913 citationsauthor #5
Abstract 3880:In vivoactivities of TP-2846: a novel tetracycline antileukemia agent
20190 citationsauthor #8
Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling
201924 citationsauthor #10
Association Between Serum Prealbumin Level and Outcomes in Prevalent Kidney Transplant Recipients.
201910 citationsauthor #5
Paradoxical behavior of time to RECIST progression as a metric for treatment effect.
20170 citationsauthor #6
Modeling Tumor Growth in Animals and Humans: An Evolutionary Approach
20163 citationsauthor #2
4. Image Processing
20150 citationsauthor #3
Abstract 3759: Xenograft rebound kinetics are consistent with the founder effect
20150 citationsauthor #5
Appendix A: Websites and Additional Information on Instruments, Reagents, and Instruction
20150 citationsauthor #3
Supervised Machine Learning
20153 citationsauthor #2
Using preclinical PD/E correlations to derive an optimal PD threshold for phase-1 decision-making.
20150 citationsauthor #10
The pharmacokinetic driver of thrombocytopenia and its implications for clinical dose schedule optimization.
20150 citationsauthor #6
Abstract 4527: Dosing schedule effects on combination activity from first principles
20150 citationsauthor #4
Abstract 1636: A model-based approach toward clinical pipeline optimization
20151 citationsauthor #7
Designing Robust Assays
20150 citationsauthor #1
Preclinical Pharmacokinetic/Pharmacodynamic Modeling and Simulation in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
201550 citationsauthor #3
Abstract 4520: Biological coupling: Drug synergy, cross-resistance, and schedule effects in combination therapy
20150 citationsauthor #5
Analyzing Cell‐Level Data
20150 citationsauthor #3
Abstract B154: Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination
20152 citationsauthor #12
Appendix C: Hypothesis Testing for High Content Data: A Refresher
20150 citationsauthor #2
Abstract 3242: Xenograft dose-response from intra-mouse dose escalation
20150 citationsauthor #5
High Content Analysis for Tissue Samples
20150 citationsauthor #5
Designing Metrics for High Content Assays
20151 citationsauthor #1
Abstract 5337: Anin silicoplatform for characterizing ADC bystander effects
20150 citationsauthor #5
O9.4Effects of clinical uncertainties on fidelity of novel tumor response metrics and RECIST
20150 citationsauthor #3
Utility of perecnt growth-rate inhibition (% GRI), a tumor growth-rate based metric to more accurately estimate response rate and magnitude of anti-tumor agents.
20150 citationsauthor #6
Applications of Pathology-Assisted Image Analysis of Immunohistochemistry-Based Biomarkers in Oncology
201423 citationsauthor #3
Abstract 698: Variability in xenograft growth rates can be explained by intra-tumor evolutionary dynamics
20140 citationsauthor #8
Abstract 3746: Anticipating the maximum tolerated dose for combinations based on early toxicity signals
20140 citationsauthor #7
Abstract 791: Rational dose optimization for multi-drug cocktails
20140 citationsauthor #8
Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
201434 citationsauthor #4
Abstract 372: Choosing the right schedule for progression free survival: A systems pharmacology approach
20140 citationsauthor #10
An introduction to high content screening : imaging technology, assay development, and data analysis in biology and drug discovery
201411 citationsauthor #3
Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
201417 citationsauthor #3
Abstract 4649: Using pharmacokinetic/efficacy modeling to identify the optimal schedule for MLN0264, an anti- guanylyl cyclase C (GCC) antibody-drug conjugate, in a range of xenograft models
20141 citationsauthor #7
Plk1 Inhibition Causes Post-Mitotic DNA Damage and Senescence in a Range of Human Tumor Cell Lines
201450 citationsauthor #2
Abstract 365: Using radionuclear imaging and mechanistic modeling to assess the therapeutic potential of antibody-drug conjugates (ADCs)
20140 citationsauthor #8
493 Preclinical pharmacokinetic (PK)/pharmacodynamic (PD)/Efficacy modeling for MLN2480, an investigational pan-RAF kinase inhibitor, in A375 and SKMEL-2 human melanoma xenografts
20140 citationsauthor #9
255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor models
20144 citationsauthor #8
High Content Analytics
20140 citationsauthor #3
Abstract 3747: Predicting Maximum Tolerated Dose during Phase I using anticipatory toxicity models
20140 citationsauthor #8
Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
201316 citationsauthor #3
Abstract B214: Application of an evolutionary model of cancer cell response to dose-response viability curves to assess the potential for pre-existing resistance.
20131 citationsauthor #9
Abstract A137: Combinatorial therapy design in cancer as a directed attack on the hubs of a scale-free network.
20130 citationsauthor #2
Abstract 2791: Just how noisy is xenograft data? Using growth rate modeling and bootstrapping to optimize xenograft study design.
20130 citationsauthor #7
Abstract A59: Treatment with targeted anticancer agent affects rapidly growing subclones: An integrated in vitro/in silico analysis of clonal heterogeneity in soft agar.
20130 citationsauthor #12
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
201321 citationsauthor #12
Abstract B213: Toward better preclinical combination studies: Using constrained optimization techniques in combination dosage and study design.
20130 citationsauthor #9
Abstract 3411: Mathematical model of the cell cycle to determine mechanism of action and optimize dosing schedule.
20130 citationsauthor #7
Abstract 5229: An integratedin vitro/in silicoplatform to study the evolutionary dynamics of resistance to cancer therapy .
20130 citationsauthor #15
Abstract 1169: Rational dose and schedule selection for the combination of paclitaxel and the investigational agent alisertib in recurrent ovarian cancer: optimization of therapeutic index based on translational hematological toxicity and exposure-efficacy modeling.
20131 citationsauthor #5
Abstract 3532: Preclinical-to-clinical translation of optimal schedule for MLN0128, an investigational novel small-molecule selective mTOR1/2 inhibitor, based on exposure-efficacy modeling.
20130 citationsauthor #13
Taxmann's transfer pricing digest: a complete and authentic transfer pricing case book incorporating judgments of supreme court/high courts/ITAT
20130 citationsauthor #1
Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.
20135 citationsauthor #3
Abstract A216: Combination schedule optimization through preclinical PK-efficacy modeling of an investigational novel-novel combination: A case study of MLN0128 an mTORC1/2 inhibitor with MLN1117 a PI3Kα isoform selective inhibitor.
20132 citationsauthor #5
256 Mechanism-based Preclinical PK/PD/E Relationships for Alisertib, an Investigational Small-molecule Inhibitor of Aurora A Kinase, in a Range of Human Solid Tumor Xenografts
20120 citationsauthor #10
Abstract 3739: TAK-733, an investigational, selective MEK1/2 inhibitor, in combination with alisertib (MLN8237), an investigational, selective Aurora A kinase inhibitor is tolerated and results in additive to synergistic antitumor activity: Results from In Vivo Studies
20122 citationsauthor #4
487 Evaluation of Predictive Biomarkers for the Antineoplastic Effect of TAK-733, a Novel Investigational Allosteric Inhibitor of MEK1/2
20120 citationsauthor #10
Current and Next Generation Antimitotic Therapies in Cancer
20127 citationsauthor #3
Abstract 3738: A rationale for combining the targeted investigational agents TAK-733, a MEK1/2 inhibitor, with alisertib (MLN8237), an Aurora A kinase inhibitor, for cancer therapy
20124 citationsauthor #7
Abstract B136: Application of a mathematical model to understand the cell cycle progression effects of MEK1/2 kinase inhibition using the investigational small-molecule allosteric inhibitor TAK-733.
20110 citationsauthor #7
Clinical Studies Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN 8054 , a Small-Molecule Inhibitor of Aurora A Kinase
20111 citationsauthor #1
Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
2011291 citationsauthor #3
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
201148 citationsauthor #1
Cancer Therapy : Preclinical Characterization of Alisertib ( MLN 8237 ) , an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
20112 citationsauthor #3
600 Preclinical pharmacokinetics–pharmacodynamics (PK-PD) modeling of TAK-733, an investigational MEK inhibitor
20102 citationsauthor #2
Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics
201084 citationsauthor #13
Study of the Selective Aurora A Kinase Inhibitor 8054 in Patients with Advanced Solid Tumors : Safety , Ther rmacokinetics , and Pharmacodynamics
20101 citationsauthor #13
Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.
20109 citationsauthor #9
The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents
200961 citationsauthor #2
93 POSTER Phase I assessment of mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase
20084 citationsauthor #1

TIMELINE

2004 53 citations

2006 42 citations

2007 405 citations

2008 8 citations

2009 61 citations

2010 96 citations

2011 342 citations

2012 13 citations

2013 46 citations

2014 140 citations

2015 57 citations

2016 3 citations

2017 0 citations

2019 47 citations

2020 44 citations

2021 144 citations

2022 48 citations

2023 19 citations

A. Chakravarty

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT